Lexicon Pharmaceuticals Inc (NASDAQ: LXRX): The Best-Of-Breed For Investing?

Currently, there are 244.93M common shares owned by the public and among those 238.79M shares have been available to trade.

Insiders at the company have transacted a total of 56 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 47 of these insider trades were purchases, accounting for 29,821,074 shares. Insider sales of the common stock occurred on 9 occasions, with total insider shares sold totaling 178,167 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The company’s stock has a 5-day price change of 42.44% and 182.13% over the past three months. LXRX shares are trading 90.85% year to date (YTD), with the 12-month market performance up to 26.41% higher. It has a 12-month low price of $0.92 and touched a high of $3.79 over the same period. LXRX has an average intraday trading volume of 3.11 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 63.45%, 92.96%, and 62.77% respectively.

Institutional ownership of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) shares accounts for 76.05% of the company’s 244.93M shares outstanding.

It has a market capitalization of $715.20M and a beta (3y monthly) value of 1.26. The earnings-per-share (ttm) stands at -$0.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.75% over the week and 10.04% over the month.

Analysts forecast that Lexicon Pharmaceuticals Inc (LXRX) will achieve an EPS of -$0.21 for the current quarter, -$0.22 for the next quarter and -$0.73 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$0.16 a year ago. Earnings per share for the fiscal year are expected to decrease by -26.81%, and 7.73% over the next financial year.

Looking at the support for the LXRX, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on March 07, 2023, with the firm’s price target at $3.

Most Popular

Related Posts